<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00832208</url>
  </required_header>
  <id_info>
    <org_study_id>AMBI 0106</org_study_id>
    <nct_id>NCT00832208</nct_id>
  </id_info>
  <brief_title>Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL</brief_title>
  <official_title>Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With Visceral Leishmaniasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drugs for Neglected Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Addis Ababa University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Drugs for Neglected Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II/III open, comparative dose trial to find the lowest single dose of&#xD;
      AmBisome for the treatment of primary, symptomatic visceral leishmaniasis(VL), in HIV&#xD;
      negative patients. In this trial, the minimum effective dose will be determined in a&#xD;
      sequential step, dose escalation design, which minimises the number of patients exposed to&#xD;
      low, potentially inadequate doses and provides contemporaneous comparative data against the&#xD;
      manufacturer's recommended dose schedule in this indication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy variable is parasitological clearance with no relapse at 6 months post treatment (ie definitive cure) assessed by clinical status and confirmed by splenic or bone marrow aspiration.</measure>
    <time_frame>at 6 months post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parasitological clearance at day 30.</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Visceral Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>Ambisome control:</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ambisome, Total dose 21.0 mg given as 7 x 3mg on days 1,2,3,4,5, and 14 and 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ambisome test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose Ambisome in sequence(7.5 / 10.0/ 12.5 / 15.0mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal amphotericin B (Ambisome)</intervention_name>
    <description>21.0 mg/kg total dose. Given iv as 3mg/kg/day on days 1,2,3,4,5, and 14 and 21</description>
    <arm_group_label>Ambisome control:</arm_group_label>
    <other_name>Ambisome</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal amphotericin B (Ambisome)</intervention_name>
    <description>liposomal amphotericin b given intravenously as single dose at 7.5 mg/kg increasing to 10, 12.5 and 15.0mg/kg depending on results of interim analyses.</description>
    <arm_group_label>Ambisome test</arm_group_label>
    <other_name>Ambisome</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female adults and children aged 4 years or older with no upper age limit (in&#xD;
             accordance with manufacturer's instructions)&#xD;
&#xD;
          -  Acute, symptomatic, VL proven by parasitological examination of splenic aspirate (or&#xD;
             bone marrow aspirate) with initial parasite index of at least 2+&#xD;
&#xD;
          -  Haemoglobin &gt;4g/dL&#xD;
&#xD;
          -  Fever for more than 2 weeks&#xD;
&#xD;
          -  Living within reachable distance of the trial site to enable attendance for follow-up&#xD;
             visits&#xD;
&#xD;
          -  Written informed consent to participate (for children, by parent or guardian)&#xD;
&#xD;
          -  HIV negative status&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients 'in extremis' with signs/symptoms indicative of severe VL&#xD;
&#xD;
          -  Patients who have received any anti-leishmanial treatment within the last 6 months&#xD;
&#xD;
          -  Patients who have received any investigational (unlicensed) drugs during 6 months&#xD;
             before recruitment&#xD;
&#xD;
          -  Known underlying chronic disease, such as severe cardiac, pulmonary, renal, or hepatic&#xD;
             impairment.&#xD;
&#xD;
          -  Renal function tests (serum creatinine) outside the normal range&#xD;
&#xD;
          -  Liver function tests more than 3 times the normal range at study entry&#xD;
&#xD;
          -  Platelet count less than 40,000/ mm3&#xD;
&#xD;
          -  Known alcohol abuse&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Concomitant acute drug usage for malaria and bacterial infection, pneumonia within&#xD;
             last 7 days&#xD;
&#xD;
          -  Known hypersensitivity to AmBisome or amphotericin B&#xD;
&#xD;
          -  Any other condition which may invalidate the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sisay Yifru, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gondar University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arba Minch LRTC</name>
      <address>
        <city>Arba Minch</city>
        <country>Ethiopia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gondar</name>
      <address>
        <city>Gondar</city>
        <country>Ethiopia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kassab Hospital</name>
      <address>
        <city>Kassab</city>
        <state>Gedarif</state>
        <country>Sudan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ethiopia</country>
    <country>Sudan</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>January 29, 2009</study_first_submitted>
  <study_first_submitted_qc>January 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2009</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Visceral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

